Schedule 13G ownership disclosure
THERAVANCE BIOPHARMA INC
Ordinary Share $0.00001 par value · CUSIP: G8807B106
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Newtyn Management, LLC
Shares: 4,757,403.00 · Class: 9.7%
- Newtyn TE Partners, LP
Shares: 2,902,002.00 · Class: 5.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001493152-25-006843
- Form type
- SCHEDULE 13G/A
- Filer
- Newtyn Management, LLC
- CIK
- CIK 1569241
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership